A recent Health Canada safety advisory comes following an updated safety review of breast implants and the associated risk of BIA-ALCL. According to the April 6, 2022 Health Canada advisory "Advisory - Updated safety review of breast implants underscores the continuing importance of monitoring for cancer; increased risk with highly textured … [Read more...]
FDA Sets New Regulations for Breast Implant Manufacturers
An October 2021 article, "FDA sets stronger safety warnings for breast implants", addresses the Food and Drug Administration's (FDA) new requirements for breast implant manufacturers. The new regulations will require patients receive detailed information about the potential risks and complications of implants prior to receiving surgery. However, … [Read more...]
Certain Aerosol Antiperspirants Found to Contain High Levels of Benzene
As previously mentioned in our June 2021 article, “Are Benzene Contaminated Sunscreens Safe to Use?“, and August 2021 article, "Johnson & Johnson Recalls Neutrogena and Aveeno Sunscreen Over Benzene Contamination Concerns", popular sunscreen manufacturer Johnson & Johnson has issued a voluntary recall of five Neutrogena and Aveeno aerosol … [Read more...]
Tongue: the unusual site in malignant pleural mesothelioma
Malignant mesotheliomas (MMs) are malignancies of the mesothelium, with primary deposits originating in the pleura, peritoneum, pericardium and the tunica vaginalis (ie, testicular). Metastatic spread is commonly reported to affect the liver, adrenal glands, kidney and contralateral lung (in cases of malignant pleural mesothelioma). Metastases to … [Read more...]
A 2021 Look at the Increased Risk of Elmiron-associated Pigmentary Maculopathy
We have reported previously on Elmiron-related eye damage, particularly that long-term use of the interstitial cystitis treatment drug Elmiron has been linked to maculopathy eye damage. In this post, we present a 2021 Elmiron medical journal article wherein it is estimated that around 20% of interstitial cystitis patients with long-term Elmiron use … [Read more...]
Testing Shows High Levels of Benzene Found In Hand Sanitizers
Valisure, a Connecticut-based online pharmacy known for testing products for quality and consistency, has found that some hand sanitizers made widely available during the early months of the coronavirus pandemic in 2020 may contain high levels of benzene. Benzene is a chemical that has been used in many different industries, but prolonged … [Read more...]
Are Heart Problems and Cancers JAK Inhibitors Drug Class Safety Issues?
Since the February 2021 FDA alert about Xeljanz-associated heart problems and possible Xeljanz-related cancers was issued, we have been watching for any related drug safety developments concerning Olumiant and Rinvoq. The reason being there has been some concern that those adverse drug events and side effects risks may apply to those other two … [Read more...]
Effect of Asbestos Exposure on the Frequency of EGFR Mutations and ALK/ROS1 Rearrangements in Patients With Lung Adenocarcinoma: A Multicentric Study
Objective: The aim of this study is to investigate the effect of asbestos exposure on cancer-driver mutations. Methods: Between January 2014 and September 2018, epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK), and c-ros oncogene 1 receptor tyrosine kinase gene (ROS1) alterations, demographic … [Read more...]
Some Information About Our Monthly Law Firm Newsletter
The Lamb Law Office Newsletter is a monthly communication from our law firm to help keep you up to date with some of the cases that we are working on for clients at the present time. In addition, we provide at least one information resource item per month, which you or someone you know might find helpful from time to time. Past … [Read more...]
New Xeljanz Warnings From FDA in 2021; Are Other JAK Inhibitors Next?
After the January 2021 release of limited data from a Xeljanz safety trial which often goes by its short name, ORAL Surveillance, some experts raised the possibility that there may consequences for other drugs in the Janus kinase (JAK) inhibitors class of drugs. Specifically, some have asked whether the FDA may extend its new Xeljanz warnings about … [Read more...]
- 1
- 2
- 3
- 4
- Next Page »